Skip to main content
. 2007 Feb 21;13(7):1079–1084. doi: 10.3748/wjg.v13.i7.1079

Figure 2.

Figure 2

Profiles of the mean 13CO2 breath excretion (▲) and serum TUDCA concentrations (■) plotted against time. Data were collected after administration of the Shellac-coated tablet containing 10% w/w of 13C-butyrate and two gelatine capsules containing 250 mg each of TUDCA. Data are expressed as mean ± SD in 12 healthy subjects (A) and 12 Crohn’s disease patients (B).